



Using Estrogen to Treat Breast Cancer

Lead researchers: Todd Miller, PhD and Gary Schwartz, MD

Written in partnership with Community Research Ambassadors: Laura and Marcy

Why we are doing this research

The most common breast cancer type is driven by estrogen, and successful therapy often blocks the estrogen. Surprisingly, high-dose estrogen therapy can also be effective against previously-treated, hormone-receptive metastatic breast cancer. Based on what we've seen in the lab, we wanted to see if alternating high-dose estrogen and blocking estrogen would be beneficial to women with metastatic breast cancer.

What we are doing

We have enrolled 18 women with metastatic breast cancer who have already received an average of two different treatments, and we are continuing to enroll patients in this trial. We are evaluating whether alternating high-dose estrogen with blocking estrogen production in the body will slow or halt tumor growth.

We will report findings in 2022.

What we've learned so far

The clinical trial participants' breast cancers have been controlled, on average, for 7-8 months since they began treatment. No patient has had significant side effects.

Why this is important

We are going to use the findings from our current trial to inform the design of the next trial, in which we will be able to determine which features of breast cancer make it more likely to respond to estrogen.

Visit <https://cancer.dartmouth.edu/patients-families/find-clinical-trial/trial/D14122> to learn more about our ongoing trial.

Our research was made possible with funds raised by our community through their participation in The Prouty.